| Year |
Citation |
Score |
| 2018 |
Shevell LM, Lee E, Dhodapkar R, Dykas D, Popa A, Ma D, Bar N, Baluha A, Burns AJ, Ochoa Chaar CI, Dupont A, Gu S, Halene S, Luciano R, Marien R, ... ... Sayeski PP, et al. Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism Blood. 132: 2506-2506. DOI: 10.1182/Blood-2018-99-115529 |
0.769 |
|
| 2018 |
Drusbosky LM, Hawkins KE, Meacham A, Wise E, Singh NK, Kumar C, Vasista SM, Suseela RP, Abbasi T, Vali S, Tohyama K, Albitar M, Sayeski PP, Cogle CR. Abstract 4285: Genomics-driven clustering of disease-related biomarkers identifies therapeutic options in myelodysplastic syndromes (MDS) Cancer Research. 78: 4285-4285. DOI: 10.1158/1538-7445.Am2018-4285 |
0.304 |
|
| 2017 |
Lee EJ, Dykas DJ, Leavitt AD, Camire RM, Ebberink E, García de Frutos P, Gnanasambandan K, Gu SX, Huntington JA, Lentz SR, Mertens K, Parish CR, Rezaie AR, Sayeski PP, Cromwell C, et al. Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Advances. 1: 1224-1237. PMID 29296762 DOI: 10.1182/Bloodadvances.2017005249 |
0.764 |
|
| 2016 |
Kiss R, Bajusz D, Baskin R, Tóth K, Monostory K, Sayeski PP, Keserű GM. Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells. Archiv Der Pharmazie. PMID 27862215 DOI: 10.1002/Ardp.201600246 |
0.433 |
|
| 2016 |
Kobayashi SS, Vali S, Kumar A, Singh N, Abbasi T, Sayeski PP. Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines. Oncotarget. PMID 27056884 DOI: 10.18632/Oncotarget.8540 |
0.35 |
|
| 2015 |
Klein S, Rick J, Lehmann J, Schierwagen R, Schierwagen IG, Verbeke L, Hittatiya K, Uschner FE, Manekeller S, Strassburg CP, Wagner KU, Sayeski PP, Wolf D, Laleman W, Sauerbruch T, et al. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut. PMID 26385087 DOI: 10.1136/Gutjnl-2015-309600 |
0.421 |
|
| 2015 |
Sayeski PP, Vali S, Kumar A, Singh N, Kobayashi S, Abbasi T. Abstract 4978: Identification and therapeutic targeting of signaling pathways in Ruxolitinib resistant cells Cancer Research. 75: 4978-4978. DOI: 10.1158/1538-7445.Am2015-4978 |
0.376 |
|
| 2014 |
Baskin R, Park SO, Keser? GM, Bisht KS, Wamsley HL, Sayeski PP. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo. Plos One. 9: e105568. PMID 25162558 DOI: 10.1093/Neuonc/Nou265.4 |
0.466 |
|
| 2014 |
Jin X, Zhao W, Kirabo A, Park SO, Ho WT, Sayeski PP, Zhao ZJ. Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 193: 477-84. PMID 24920845 DOI: 10.4049/Jimmunol.1301946 |
0.622 |
|
| 2014 |
Cogle CR, Tohyama K, Vali S, Kumar A, Singh NK, Tiwari KK, Tyagi A, Abbasi T, Sayeski PP. A Novel Simulation Method for Mapping Dysregulated Pathways and Predicting Effective Therapeutics in the Myelodysplastic Syndromes Blood. 124: 5595-5595. DOI: 10.1182/Blood.V124.21.5595.5595 |
0.375 |
|
| 2014 |
Cogle CR, Trikha G, Sayeski PP, Vali S, Kumar A, Singh NK, Nair PR, Lala DA, Basu K, Abbasi T, Albitar M. A Novel Method of Using Molecular Profiling in Myelodysplastic Syndromes to Predict Patient-Specific Potential Therapeutics Blood. 124: 5591-5591. DOI: 10.1182/Blood.V124.21.5591.5591 |
0.374 |
|
| 2014 |
Sayeski PP, Vali S, Kumar A, Park S, Singh NK, Tyagi A, Abbasi T, Cogle CR. Personalized Therapy Design for MPN Using Predictive Simulation Methodology with in Vitro, Ex Vivo, and in Vivo Validatio Blood. 124: 3212-3212. DOI: 10.1182/Blood.V124.21.3212.3212 |
0.391 |
|
| 2013 |
Park SO, Wamsley HL, Bae K, Hu Z, Li X, Choe SW, Slayton WB, Oh SP, Wagner KU, Sayeski PP. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. Plos One. 8: e59675. PMID 23544085 DOI: 10.1371/Journal.Pone.0059675 |
0.356 |
|
| 2013 |
Rhodes S, Copland M, Hopcroft L, Sayeski P, Wheadon H. Identification of JAK2 dependent transcriptional regulators in CML Experimental Hematology. 41: S47. DOI: 10.1016/J.Exphem.2013.05.186 |
0.431 |
|
| 2012 |
Kirabo A, Park SO, Wamsley HL, Gali M, Baskin R, Reinhard MK, Zhao ZJ, Bisht KS, Keserű GM, Cogle CR, Sayeski PP. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. The American Journal of Pathology. 181: 858-65. PMID 22796437 DOI: 10.1016/J.Ajpath.2012.05.033 |
0.651 |
|
| 2012 |
Gnanasambandan K, Magis AT, Sayeski PP. A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L. Molecular and Cellular Biochemistry. 367: 125-40. PMID 22584586 DOI: 10.1007/S11010-012-1326-7 |
0.78 |
|
| 2012 |
Baskin R, Gali M, Park SO, Zhao ZJ, Keseru GM, Bisht KS, Sayeski PP. Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation. Bioorganic & Medicinal Chemistry Letters. 22: 1402-7. PMID 22227213 DOI: 10.1016/J.Bmcl.2011.12.042 |
0.394 |
|
| 2012 |
Majumder A, Magis AT, Park SO, Figueroa NC, Baskin R, Kirabo A, Allan RW, Zhao ZJ, Bisht KS, Keseru GM, Sayeski PP. A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth. Experimental Hematology. 40: 22-34. PMID 22019628 DOI: 10.1016/J.Exphem.2011.10.003 |
0.806 |
|
| 2012 |
Baskin R, Sayeski PP. Angiotensin II mediates cell survival through upregulation and activation of the serum and glucocorticoid inducible kinase 1. Cellular Signalling. 24: 435-42. PMID 21963429 DOI: 10.1016/J.Cellsig.2011.09.016 |
0.391 |
|
| 2012 |
Jin X, Zhao W, Kirabo A, Park S, Ho W, Sayeski PP, Zhao ZJ. Aberrant Functions of Mast Cells Are Involved in Pruritus Associated with Polycythemia Vera Blood. 120: 1756-1756. DOI: 10.1182/Blood.V120.21.1756.1756 |
0.672 |
|
| 2011 |
Kirabo A, Park SO, Majumder A, Gali M, Reinhard MK, Wamsley HL, Zhao ZJ, Cogle CR, Bisht KS, Keserü GM, Sayeski PP. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia (New York, N.Y.). 13: 1058-68. PMID 22131881 DOI: 10.1593/Neo.111112 |
0.804 |
|
| 2011 |
Gnanasambandan K, Sayeski PP. A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken. Current Medicinal Chemistry. 18: 4659-73. PMID 21864276 DOI: 10.2174/092986711797379267 |
0.823 |
|
| 2011 |
Majumder A, Kirabo A, Karrupiah K, Tsuda S, Caldwell-Busby J, Cardounel AJ, Keseru GM, Sayeski PP. Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments. Biochemistry. 50: 7774-86. PMID 21823612 DOI: 10.1021/Bi200847N |
0.82 |
|
| 2011 |
Sayyah J, Gnanasambandan K, Kamarajugadda S, Tsuda S, Caldwell-Busby J, Sayeski PP. Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation. Cellular Signalling. 23: 1806-15. PMID 21726629 DOI: 10.1016/J.Cellsig.2011.06.015 |
0.797 |
|
| 2011 |
Kirabo A, Oh SP, Kasahara H, Wagner KU, Sayeski PP. Vascular smooth muscle Jak2 deletion prevents angiotensin II-mediated neointima formation following injury in mice. Journal of Molecular and Cellular Cardiology. 50: 1026-34. PMID 21420414 DOI: 10.1016/J.Yjmcc.2011.03.005 |
0.606 |
|
| 2011 |
Kirabo A, Kearns PN, Jarajapu YP, Sasser JM, Oh SP, Grant MB, Kasahara H, Cardounel AJ, Baylis C, Wagner KU, Sayeski PP. Vascular smooth muscle Jak2 mediates angiotensin II-induced hypertension via increased levels of reactive oxygen species. Cardiovascular Research. 91: 171-9. PMID 21354995 DOI: 10.1093/Cvr/Cvr059 |
0.587 |
|
| 2011 |
Kirabo A, Embury J, Kiss R, Polgár T, Gali M, Majumder A, Bisht KS, Cogle CR, Keseru GM, Sayeski PP. The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo. The Journal of Biological Chemistry. 286: 4280-91. PMID 21127060 DOI: 10.1074/Jbc.M110.200774 |
0.818 |
|
| 2011 |
Sayeski PP, Kirabo A, Park S, Gali M, Reinhard M, Wamsley HL, Zhao ZJ, Bisht KS, Cogle CR, Keseru GM. The Jak2 Kinase Inhibitor, G6, Reduces the Mutant Burden and Reverses Marrow Fibrosis in a Mouse Model of Jak2-V617F Mediated PMF, Blood. 118: 3858-3858. DOI: 10.1182/Blood.V118.21.3858.3858 |
0.656 |
|
| 2011 |
Majumder A, Kirabo A, Karrupiah K, Tsuda S, Caldwell-Busby J, Cardounel AJ, Sayeski PP. Abstract 5127: G6-mediated inhibition of Jak2 tyrosine kinase correlates with the cleavage and cellular reorganization of vimentin Cancer Research. 71: 5127-5127. DOI: 10.1158/1538-7445.Am2011-5127 |
0.82 |
|
| 2010 |
Baskin R, Majumder A, Sayeski PP. The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors. Current Medicinal Chemistry. 17: 4551-8. PMID 21062251 DOI: 10.2174/092986710794182953 |
0.784 |
|
| 2010 |
Gnanasambandan K, Magis A, Sayeski PP. The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. Biochemistry. 49: 9972-84. PMID 20958061 DOI: 10.1021/Bi1014858 |
0.789 |
|
| 2010 |
Majumder A, Govindasamy L, Magis A, Kiss R, Polgár T, Baskin R, Allan RW, Agbandje-McKenna M, Reuther GW, Keseru GM, Bisht KS, Sayeski PP. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core. The Journal of Biological Chemistry. 285: 31399-407. PMID 20667821 DOI: 10.1074/Jbc.M110.168211 |
0.799 |
|
| 2010 |
Kiss R, Sayeski PP, Keserũ GM. Recent developments on JAK2 inhibitors: a patent review. Expert Opinion On Therapeutic Patents. 20: 471-95. PMID 20205617 DOI: 10.1517/13543771003639436 |
0.475 |
|
| 2010 |
Kirabo A, Sayeski PP. Jak2 tyrosine kinase: A potential therapeutic target for AT1 receptor mediated cardiovascular disease Pharmaceuticals. 3: 3478-3493. DOI: 10.3390/Ph3113478 |
0.631 |
|
| 2010 |
Majumder A, Sayeski PP. Tyrosine-protein kinase JAK2 inhibitors for the treatment of myeloproliferative neoplasms Drugs of the Future. 35: 651-660. DOI: 10.1358/Dof.2010.035.08.1514131 |
0.795 |
|
| 2010 |
Park S, Gnanasambandan K, Sayeski PP. Jak2 Plays a Critical and Non-Redundant Role In Hematopoiesis throughout Pre- and Post-Natal Life Blood. 116: 2238-2238. DOI: 10.1182/Blood.V116.21.2238.2238 |
0.771 |
|
| 2009 |
Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorganic & Medicinal Chemistry Letters. 19: 3598-601. PMID 19447617 DOI: 10.1016/J.Bmcl.2009.04.138 |
0.821 |
|
| 2009 |
Sayyah J, Sayeski PP. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Current Oncology Reports. 11: 117-24. PMID 19216843 DOI: 10.1007/S11912-009-0018-2 |
0.806 |
|
| 2009 |
Cuesta-Domínguez A, Ortega M, Ormazabal C, Santos-Roncero M, Galán-Díez M, Steegmann JL, Arranz E, Figuera MA, Sayyah J, Sayeski PP, Vizmanos JL, Bueren JA, Rio P, Fernandez-Ruiz E. Transforming and Tumorogenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosin-Kinase. Blood. 114: 4683-4683. DOI: 10.1182/Blood.V114.22.4683.4683 |
0.497 |
|
| 2008 |
Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Molecular Cancer Therapeutics. 7: 2308-18. PMID 18723478 DOI: 10.1158/1535-7163.Mct-08-0279 |
0.837 |
|
| 2008 |
McDoom I, Ma X, Kirabo A, Lee KY, Ostrov DA, Sayeski PP. Identification of tyrosine 972 as a novel site of Jak2 tyrosine kinase phosphorylation and its role in Jak2 activation. Biochemistry. 47: 8326-34. PMID 18636744 DOI: 10.1021/Bi800867D |
0.703 |
|
| 2007 |
Godeny MD, Sayeski PP. Jak2 tyrosine kinase and cancer: how good cells get HiJAKed. Anti-Cancer Agents in Medicinal Chemistry. 7: 643-50. PMID 18045059 DOI: 10.2174/187152007782330105 |
0.448 |
|
| 2007 |
Ma X, Sayeski PP. Identification of tubulin as a substrate of Jak2 tyrosine kinase and its role in Jak2-dependent signaling. Biochemistry. 46: 7153-62. PMID 17530781 DOI: 10.1021/Bi700101N |
0.483 |
|
| 2007 |
Godeny MD, Sayyah J, VonDerLinden D, Johns M, Ostrov DA, Caldwell-Busby J, Sayeski PP. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor. Cellular Signalling. 19: 600-9. PMID 17027227 DOI: 10.1016/J.Cellsig.2006.08.010 |
0.805 |
|
| 2007 |
Sayyah J, Allen RW, Braylan RC, Keseru GM, Sayeski PP. Identification and Characterization of a Series of Novel Jak2 Small Molecule Inhibitor Compounds. Blood. 110: 539-539. DOI: 10.1182/Blood.V110.11.539.539 |
0.822 |
|
| 2006 |
Frenzel K, Wallace TA, McDoom I, Xiao HD, Capecchi MR, Bernstein KE, Sayeski PP. A functional Jak2 tyrosine kinase domain is essential for mouse development. Experimental Cell Research. 312: 2735-44. PMID 16887119 DOI: 10.1016/J.Yexcr.2006.05.004 |
0.822 |
|
| 2006 |
Godeny MD, Sayeski PP. ANG II-induced cell proliferation is dually mediated by c-Src/Yes/Fyn-regulated ERK1/2 activation in the cytoplasm and PKCzeta-controlled ERK1/2 activity within the nucleus. American Journal of Physiology. Cell Physiology. 291: C1297-307. PMID 16723512 DOI: 10.1152/Ajpcell.00617.2005 |
0.436 |
|
| 2006 |
Godeny MD, Sayeski PP. ERK1/2 regulates ANG II-dependent cell proliferation via cytoplasmic activation of RSK2 and nuclear activation of elk1. American Journal of Physiology. Cell Physiology. 291: C1308-17. PMID 16723511 DOI: 10.1152/Ajpcell.00618.2005 |
0.451 |
|
| 2006 |
Wallace TA, Sayeski PP. Jak2 tyrosine kinase: a mediator of both housekeeping and ligand-dependent gene expression? Cell Biochemistry and Biophysics. 44: 213-22. PMID 16456223 DOI: 10.1385/Cbb:44:2:213 |
0.8 |
|
| 2006 |
Sayyah J, Ostrov D, Sayeski P. Identification and Characterization of a Novel Jak2 Tyrosine Kinase Inhibitor. Blood. 108: 3604-3604. DOI: 10.1182/Blood.V108.11.3604.3604 |
0.838 |
|
| 2005 |
Wallace TA, Xia SL, Sayeski PP. Jak2 tyrosine kinase prevents angiotensin II-mediated inositol 1,4,5 trisphosphate receptor degradation. Vascular Pharmacology. 43: 336-45. PMID 16257270 DOI: 10.1016/J.Vph.2005.08.022 |
0.789 |
|
| 2005 |
Sandberg EM, Ma X, He K, Frank SJ, Ostrov DA, Sayeski PP. Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. Journal of Medicinal Chemistry. 48: 2526-33. PMID 15801842 DOI: 10.1021/Jm049470K |
0.503 |
|
| 2004 |
Sandberg EM, VonDerLinden D, Ostrov DA, Sayeski PP. Jak2 tyrosine kinase residues glutamic acid 1024 and arginine 1113 form a hydrogen bond interaction that is essential for Jak-STAT signal transduction. Molecular and Cellular Biochemistry. 265: 161-9. PMID 15543946 DOI: 10.1023/B:Mcbi.0000044393.67980.99 |
0.48 |
|
| 2004 |
Sandberg EM, Wallace TA, Godeny MD, VonDerLinden D, Sayeski PP. Jak2 tyrosine kinase: a true jak of all trades? Cell Biochemistry and Biophysics. 41: 207-32. PMID 15475610 DOI: 10.1385/Cbb:41:2:207 |
0.816 |
|
| 2004 |
Jiang J, Wang X, He K, Li X, Chen C, Sayeski PP, Waters MJ, Frank SJ. A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis. Molecular Endocrinology (Baltimore, Md.). 18: 2981-96. PMID 15345746 DOI: 10.1210/Me.2004-0102 |
0.343 |
|
| 2004 |
Wallace TA, VonDerLinden D, He K, Frank SJ, Sayeski PP. Microarray analyses identify JAK2 tyrosine kinase as a key mediator of ligand-independent gene expression. American Journal of Physiology. Cell Physiology. 287: C981-91. PMID 15189810 DOI: 10.1152/Ajpcell.00085.2004 |
0.778 |
|
| 2004 |
Sandberg EM, Sayeski PP. Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. The Journal of Biological Chemistry. 279: 34547-52. PMID 15159394 DOI: 10.1074/Jbc.M405045200 |
0.37 |
|
| 2004 |
Ma X, Sayeski PP. Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein. Protein Expression and Purification. 35: 181-9. PMID 15135391 DOI: 10.1016/J.Pep.2004.02.009 |
0.392 |
|
| 2004 |
Sandberg EM, Ma X, VonDerLinden D, Godeny MD, Sayeski PP. Jak2 tyrosine kinase mediates angiotensin II-dependent inactivation of ERK2 via induction of mitogen-activated protein kinase phosphatase 1. The Journal of Biological Chemistry. 279: 1956-67. PMID 14551204 DOI: 10.1074/Jbc.M303540200 |
0.453 |
|
| 2003 |
He K, Wang X, Jiang J, Guan R, Bernstein KE, Sayeski PP, Frank SJ. Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Molecular Endocrinology (Baltimore, Md.). 17: 2211-27. PMID 12920237 DOI: 10.1210/Me.2003-0256 |
0.438 |
|
| 2003 |
Sayeski PP, Ali MS. The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation. Experimental Cell Research. 287: 339-49. PMID 12837289 DOI: 10.1016/S0014-4827(03)00154-X |
0.455 |
|
| 2002 |
VonDerLinden D, Ma X, Sandberg EM, Gernert K, Bernstein KE, Sayeski PP. Mutation of glutamic acid residue 1046 abolishes Jak2 tyrosine kinase activity. Molecular and Cellular Biochemistry. 241: 87-94. PMID 12482029 DOI: 10.1023/A:1020829617779 |
0.506 |
|
| 2001 |
Sayeski PP, Bernstein KE. Signal transduction mechanisms of the angiotensin II type AT1-receptor: Looking beyond the heterotrimeric G protein paradigm Jraas - Journal of the Renin-Angiotensin-Aldosterone System. 2: 4-10. PMID 11881054 DOI: 10.3317/Jraas.2001.007 |
0.373 |
|
| 2001 |
Sayeski PP, Showkat Ali M, Frank SJ, Bernstein KE. The Angiotensin II-dependent Nuclear Translocation of Stat1 is Mediated by the Jak2 Protein Motif 231YRFRR Journal of Biological Chemistry. 276: 10556-10563. PMID 11152457 DOI: 10.1074/Jbc.M008856200 |
0.434 |
|
| 2000 |
Sayeski PP, Ali MS, Bernstein KE. The role of Ca2+ mobilization and heterotrimeric G protein activation in mediating tyrosine phosphorylation signaling patterns in vascular smooth muscle cells Molecular and Cellular Biochemistry. 212: 91-98. PMID 11108140 DOI: 10.1007/978-1-4615-4351-0_11 |
0.421 |
|
| 2000 |
Ali MS, Sayeski PP, Bernstein KE. Jak2 acts as both a STAT1 kinase and as a molecular bridge linking STAT1 to the angiotensin II AT1 receptor Journal of Biological Chemistry. 275: 15586-15593. PMID 10748109 DOI: 10.1074/Jbc.M908931199 |
0.409 |
|
| 1999 |
Sayeski PP, Ali MS, Safavi A, Lyles M, Kim SO, Frank SJ, Bernstein KE. A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn Journal of Biological Chemistry. 274: 33131-33142. PMID 10551884 DOI: 10.1074/jbc.274.46.33131 |
0.369 |
|
| 1999 |
Sayeski PP, Ali MS, Hawks K, Frank SJ, Bernstein KE. The angiotensin II-dependent association of Jak2 and c-Src requires the N-terminus of Jak2 and the SH2 domain of c-Src Circulation Research. 84: 1332-1338. PMID 10364571 DOI: 10.1161/01.Res.84.11.1332 |
0.408 |
|
| 1998 |
Sayeski PP, Ali MS, Semeniuk DJ, Doan TN, Bernstein KE. Angiotensin II signal transduction pathways. Regulatory Peptides. 78: 19-29. PMID 9879743 DOI: 10.1016/S0167-0115(98)00137-2 |
0.389 |
|
| 1998 |
Sayeski PP, Ali MS, Harp JB, Marrero MB, Bernstein KE. Phosphorylation of p130(Cas) by angiotensin II is dependent on c-Src, intracellular Ca2+, and protein kinase C Circulation Research. 82: 1279-1288. PMID 9648724 DOI: 10.1161/01.Res.82.12.1279 |
0.381 |
|
| 1998 |
Bernstein KE, Ali MS, Sayeski PP, Semeniuk D, Marrero MB. New insights into the cellular signaling of seven transmembrane receptors: The role of tyrosine phosphorylation Laboratory Investigation. 78: 3-7. PMID 9461117 |
0.309 |
|
| 1997 |
Ali MS, Sayeski PP, Dirksen LB, Hayzer DJ, Marrero MB, Bernstein KE. Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor Journal of Biological Chemistry. 272: 23382-23388. PMID 9287353 DOI: 10.1074/Jbc.272.37.23382 |
0.403 |
|
| 1997 |
Harp JB, Sayeski PP, Scanlon M, Bernstein KE, Marrero MB. Role of intracellular calcium in the angiotensin II-mediated tyrosine phosphorylation and dephosphorylation of PLC-γl Biochemical and Biophysical Research Communications. 232: 540-544. PMID 9125218 DOI: 10.1006/Bbrc.1997.6322 |
0.36 |
|
| Show low-probability matches. |